Syfovre vision loss cases have been reported by patients after the first time they used this injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre being associated with vision loss as well as some eye-related severe adverse reactions.
This still-developing Syfovre safety issue was next addressed by a so-called “Dear Doctor” letter that was sent to ophthalmologists by Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre, later in July 2023, after the ASRS letter.
From this July 28, 2023 item, “First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an Unexpected Safety Signal”, we get the following information:
According to the American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee, ophthalmologists have reported cases of intraocular inflammation (IOI) following the administration of Syfovre. In addition to mild-moderate IOI, these reports also include severe IOI, retinal vasculitis, and occlusive retina vasculitis (six cases at the time of writing). These events occurred between 7 and 13 days after the initial dose of Syfovre was administered.
We are investigating Syfovre vision loss cases that would be filed as drug injury lawsuits against Apellis for patients who developed occlusive retinal vasculitis or eye inflammation after receiving a Syfovre injection.
We will continue to monitor this Syfovre safety issue and report significant developments.
[Read article in full at original source]Syfovre
Free Case Evaluation
Strictly Confidential, No Obligation